{"tstamp": 1704225341.2567, "type": "chat", "model": "meditron-7b", "gen_params": {"temperature": 0.7, "top_p": 1.0, "max_new_tokens": 1024}, "start": 1704225335.9236, "finish": 1704225341.2567, "state": {"template_name": "zero_shot_medical", "system_message": "You are a helpful, respectful and honest assistant.Always answer as helpfully as possible, while being safe.Your answers should not include any harmful, unethical, racist, sexist, toxic, dangerous, or illegal content.Please ensure that your responses are socially unbiased and positive in nature.\n\nIf a question does not make any sense, or is not factually coherent, explain why instead of answering something not correct.If you don't know the answer to a question, please don't share false information.", "roles": ["User", "Assistant"], "messages": [["User", "Hi!"], ["Assistant", "Hi!\n\nIs the weather supposed to be this hot?"]], "offset": 0, "conv_id": "f661d73cfc2e46688ea786175fd38ed9", "model_name": "meditron-7b"}, "ip": "172.31.46.135"}
{"tstamp": 1704225366.9897, "type": "chat", "model": "meditron-7b", "gen_params": {"temperature": 0.7, "top_p": 1.0, "max_new_tokens": 1024}, "start": 1704225356.8548, "finish": 1704225366.9897, "state": {"template_name": "zero_shot_medical", "system_message": "You are a helpful, respectful and honest assistant.Always answer as helpfully as possible, while being safe.Your answers should not include any harmful, unethical, racist, sexist, toxic, dangerous, or illegal content.Please ensure that your responses are socially unbiased and positive in nature.\n\nIf a question does not make any sense, or is not factually coherent, explain why instead of answering something not correct.If you don't know the answer to a question, please don't share false information.", "roles": ["User", "Assistant"], "messages": [["User", "Hi!"], ["Assistant", "Hi!\n\nIs the weather supposed to be this hot?"], ["User", "Can you tell me about biomarkers in cancer research?"], ["Assistant", "Biomarkers are molecular markers in the human body that can be used to identify, diagnose, and predict prognosis of disease."]], "offset": 0, "conv_id": "f661d73cfc2e46688ea786175fd38ed9", "model_name": "meditron-7b"}, "ip": "172.31.46.135"}
{"tstamp": 1704226240.9796, "type": "chat", "model": "meditron-7b", "gen_params": {"temperature": 0.1, "top_p": 1.0, "max_new_tokens": 256}, "start": 1704226235.0749, "finish": 1704226240.9796, "state": {"template_name": "zero_shot_medical", "system_message": "You are a helpful, respectful and honest assistant.Always answer as helpfully as possible, while being safe.Your answers should not include any harmful, unethical, racist, sexist, toxic, dangerous, or illegal content.Please ensure that your responses are socially unbiased and positive in nature.\n\nIf a question does not make any sense, or is not factually coherent, explain why instead of answering something not correct.If you don't know the answer to a question, please don't share false information.", "roles": ["User", "Assistant"], "messages": [["User", "If I provide some text, can you try to identify the cancer biomarkers within it?"], ["Assistant", "Yes, I can try to identify the cancer biomarkers within it."]], "offset": 0, "conv_id": "935acfb099824c8fa2edcfa8a2d83e8b", "model_name": "meditron-7b"}, "ip": "172.31.21.150"}
{"tstamp": 1704226266.0783, "type": "chat", "model": "meditron-7b", "gen_params": {"temperature": 0.1, "top_p": 1.0, "max_new_tokens": 256}, "start": 1704226259.9812, "finish": 1704226266.0783, "state": {"template_name": "zero_shot_medical", "system_message": "You are a helpful, respectful and honest assistant.Always answer as helpfully as possible, while being safe.Your answers should not include any harmful, unethical, racist, sexist, toxic, dangerous, or illegal content.Please ensure that your responses are socially unbiased and positive in nature.\n\nIf a question does not make any sense, or is not factually coherent, explain why instead of answering something not correct.If you don't know the answer to a question, please don't share false information.", "roles": ["User", "Assistant"], "messages": [["User", "If I provide some text, can you try to identify the cancer biomarkers within it?"], ["Assistant", "Yes, I can try to identify the cancer biomarkers within it."], ["User", "The subject has a pathologic diagnosis of non-small cell lung carcinoma that is metastatic or unresectable  \nDocumented presence\n* GROUP A: kinesin family member 5B (KIF5B)-RET or related variant RET fusions\n* GROUP B: any of the following aberrations\n** NTRK fusion\n** MET overexpression, amplification, or mutation\n** AXL overexpression, amplification, or mutation\n* GROUP C: ROS1 fusion\n* GROUP D: RET-fusion post-progression on selective RET inhibitor  \nMeasurable disease by RECIST1.1  \nThe subject has a Karnofsky performance status of > 70%  \nAbsolute neutrophil count (ANC) >= 1500/mm^3 without colony stimulating factor support  \nPlatelets >= 100,000/mm^3..."], ["Assistant", "Yes, I can try to identify the cancer biomarkers within it."]], "offset": 0, "conv_id": "935acfb099824c8fa2edcfa8a2d83e8b", "model_name": "meditron-7b"}, "ip": "172.31.21.150"}
{"tstamp": 1704226301.0286, "type": "chat", "model": "meditron-7b", "gen_params": {"temperature": 0.1, "top_p": 1.0, "max_new_tokens": 256}, "start": 1704226280.9188, "finish": 1704226301.0286, "state": {"template_name": "zero_shot_medical", "system_message": "You are a helpful, respectful and honest assistant.Always answer as helpfully as possible, while being safe.Your answers should not include any harmful, unethical, racist, sexist, toxic, dangerous, or illegal content.Please ensure that your responses are socially unbiased and positive in nature.\n\nIf a question does not make any sense, or is not factually coherent, explain why instead of answering something not correct.If you don't know the answer to a question, please don't share false information.", "roles": ["User", "Assistant"], "messages": [["User", "If I provide some text, can you try to identify the cancer biomarkers within it?"], ["Assistant", "Yes, I can try to identify the cancer biomarkers within it."], ["User", "The subject has a pathologic diagnosis of non-small cell lung carcinoma that is metastatic or unresectable  \nDocumented presence\n* GROUP A: kinesin family member 5B (KIF5B)-RET or related variant RET fusions\n* GROUP B: any of the following aberrations\n** NTRK fusion\n** MET overexpression, amplification, or mutation\n** AXL overexpression, amplification, or mutation\n* GROUP C: ROS1 fusion\n* GROUP D: RET-fusion post-progression on selective RET inhibitor  \nMeasurable disease by RECIST1.1  \nThe subject has a Karnofsky performance status of > 70%  \nAbsolute neutrophil count (ANC) >= 1500/mm^3 without colony stimulating factor support  \nPlatelets >= 100,000/mm^3..."], ["Assistant", "Yes, I can try to identify the cancer biomarkers within it."], ["User", "What are the biomarkers in the above text>"], ["Assistant", "The biomarkers in the above text are RET-fusion post-progression on selective RET inhibitor, NTRK fusion, MET overexpression, amplification, or mutation, AXL overexpression, amplification, or mutation, and ROS1 fusion."]], "offset": 0, "conv_id": "935acfb099824c8fa2edcfa8a2d83e8b", "model_name": "meditron-7b"}, "ip": "172.31.21.150"}
{"tstamp": 1704226403.9975, "type": "chat", "model": "meditron-7b", "gen_params": {"temperature": 0.1, "top_p": 1.0, "max_new_tokens": 256}, "start": 1704226399.6548, "finish": 1704226403.9975, "state": {"template_name": "zero_shot_medical", "system_message": "You are a helpful, respectful and honest assistant.Always answer as helpfully as possible, while being safe.Your answers should not include any harmful, unethical, racist, sexist, toxic, dangerous, or illegal content.Please ensure that your responses are socially unbiased and positive in nature.\n\nIf a question does not make any sense, or is not factually coherent, explain why instead of answering something not correct.If you don't know the answer to a question, please don't share false information.", "roles": ["User", "Assistant"], "messages": [["User", "If I provide some text, can you try to identify the cancer biomarkers within it?"], ["Assistant", "Yes, I can try to identify the cancer biomarkers within it."], ["User", "The subject has a pathologic diagnosis of non-small cell lung carcinoma that is metastatic or unresectable  \nDocumented presence\n* GROUP A: kinesin family member 5B (KIF5B)-RET or related variant RET fusions\n* GROUP B: any of the following aberrations\n** NTRK fusion\n** MET overexpression, amplification, or mutation\n** AXL overexpression, amplification, or mutation\n* GROUP C: ROS1 fusion\n* GROUP D: RET-fusion post-progression on selective RET inhibitor  \nMeasurable disease by RECIST1.1  \nThe subject has a Karnofsky performance status of > 70%  \nAbsolute neutrophil count (ANC) >= 1500/mm^3 without colony stimulating factor support  \nPlatelets >= 100,000/mm^3..."], ["Assistant", "Yes, I can try to identify the cancer biomarkers within it."], ["User", "What are the biomarkers in the above text>"], ["Assistant", "The biomarkers in the above text are RET-fusion post-progression on selective RET inhibitor, NTRK fusion, MET overexpression, amplification, or mutation, AXL overexpression, amplification, or mutation, and ROS1 fusion."], ["User", "Yes, that is almost correct. The only one you missed is KIF5B/RET Fusion Gene. Thank you."], ["Assistant", "I am sorry, I did not know that."]], "offset": 0, "conv_id": "935acfb099824c8fa2edcfa8a2d83e8b", "model_name": "meditron-7b"}, "ip": "172.31.46.135"}
{"tstamp": 1704226458.1939, "type": "chat", "model": "meditron-7b", "gen_params": {"temperature": 0.1, "top_p": 1.0, "max_new_tokens": 256}, "start": 1704226451.7964, "finish": 1704226458.1939, "state": {"template_name": "zero_shot_medical", "system_message": "You are a helpful, respectful and honest assistant.Always answer as helpfully as possible, while being safe.Your answers should not include any harmful, unethical, racist, sexist, toxic, dangerous, or illegal content.Please ensure that your responses are socially unbiased and positive in nature.\n\nIf a question does not make any sense, or is not factually coherent, explain why instead of answering something not correct.If you don't know the answer to a question, please don't share false information.", "roles": ["User", "Assistant"], "messages": [["User", "If I provide some text, can you try to identify the cancer biomarkers within it?"], ["Assistant", "Yes, I can try to identify the cancer biomarkers within it."], ["User", "The subject has a pathologic diagnosis of non-small cell lung carcinoma that is metastatic or unresectable  \nDocumented presence\n* GROUP A: kinesin family member 5B (KIF5B)-RET or related variant RET fusions\n* GROUP B: any of the following aberrations\n** NTRK fusion\n** MET overexpression, amplification, or mutation\n** AXL overexpression, amplification, or mutation\n* GROUP C: ROS1 fusion\n* GROUP D: RET-fusion post-progression on selective RET inhibitor  \nMeasurable disease by RECIST1.1  \nThe subject has a Karnofsky performance status of > 70%  \nAbsolute neutrophil count (ANC) >= 1500/mm^3 without colony stimulating factor support  \nPlatelets >= 100,000/mm^3..."], ["Assistant", "Yes, I can try to identify the cancer biomarkers within it."], ["User", "What are the biomarkers in the above text>"], ["Assistant", "The biomarkers in the above text are RET-fusion post-progression on selective RET inhibitor, NTRK fusion, MET overexpression, amplification, or mutation, AXL overexpression, amplification, or mutation, and ROS1 fusion."], ["User", "Yes, that is almost correct. The only one you missed is KIF5B/RET Fusion Gene. Thank you."], ["Assistant", "I am sorry, I did not know that."], ["User", "Can you try again with this text?\nPatients must have evidence of disease progression prior to enrollment  \nAll patients must have received a prior platinum-based chemotherapy regimen for treatment of urothelial cancer and must now be considered refractory to platinum-based chemotherapy; patients may have received the platinum-containing regimen either in the peri-operative or metastatic setting; patients may have received any number of additional prior therapies, and may have received prior immune therapies  \nPatients must have tumor evidence of somatic genomic molecular alteration in EGFR, HER2, ERBB3, or ERBB4, from a test result generated in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory; the tumor tissue sample used to generate the qualifying report must be from a muscle-invasive or higher stage urinary tract cancer specimen (metastatic tissue is also acceptable); final determination about whether a specific tissue source or molecular genomic finding meets criteria as a qualifying result rests with the central study principal investigator (PI); germline genomic findings will not be returned to patients  \nPatients must be 18 years of age or older..."], ["Assistant", "Yes, I can try to identify the cancer biomarkers within it."]], "offset": 0, "conv_id": "935acfb099824c8fa2edcfa8a2d83e8b", "model_name": "meditron-7b"}, "ip": "172.31.46.135"}
{"tstamp": 1704226476.2841, "type": "chat", "model": "meditron-7b", "gen_params": {"temperature": 0.1, "top_p": 1.0, "max_new_tokens": 256}, "start": 1704226466.163, "finish": 1704226476.2841, "state": {"template_name": "zero_shot_medical", "system_message": "You are a helpful, respectful and honest assistant.Always answer as helpfully as possible, while being safe.Your answers should not include any harmful, unethical, racist, sexist, toxic, dangerous, or illegal content.Please ensure that your responses are socially unbiased and positive in nature.\n\nIf a question does not make any sense, or is not factually coherent, explain why instead of answering something not correct.If you don't know the answer to a question, please don't share false information.", "roles": ["User", "Assistant"], "messages": [["User", "If I provide some text, can you try to identify the cancer biomarkers within it?"], ["Assistant", "Yes, I can try to identify the cancer biomarkers within it."], ["User", "The subject has a pathologic diagnosis of non-small cell lung carcinoma that is metastatic or unresectable  \nDocumented presence\n* GROUP A: kinesin family member 5B (KIF5B)-RET or related variant RET fusions\n* GROUP B: any of the following aberrations\n** NTRK fusion\n** MET overexpression, amplification, or mutation\n** AXL overexpression, amplification, or mutation\n* GROUP C: ROS1 fusion\n* GROUP D: RET-fusion post-progression on selective RET inhibitor  \nMeasurable disease by RECIST1.1  \nThe subject has a Karnofsky performance status of > 70%  \nAbsolute neutrophil count (ANC) >= 1500/mm^3 without colony stimulating factor support  \nPlatelets >= 100,000/mm^3..."], ["Assistant", "Yes, I can try to identify the cancer biomarkers within it."], ["User", "What are the biomarkers in the above text>"], ["Assistant", "The biomarkers in the above text are RET-fusion post-progression on selective RET inhibitor, NTRK fusion, MET overexpression, amplification, or mutation, AXL overexpression, amplification, or mutation, and ROS1 fusion."], ["User", "Yes, that is almost correct. The only one you missed is KIF5B/RET Fusion Gene. Thank you."], ["Assistant", "I am sorry, I did not know that."], ["User", "Can you try again with this text?\nPatients must have evidence of disease progression prior to enrollment  \nAll patients must have received a prior platinum-based chemotherapy regimen for treatment of urothelial cancer and must now be considered refractory to platinum-based chemotherapy; patients may have received the platinum-containing regimen either in the peri-operative or metastatic setting; patients may have received any number of additional prior therapies, and may have received prior immune therapies  \nPatients must have tumor evidence of somatic genomic molecular alteration in EGFR, HER2, ERBB3, or ERBB4, from a test result generated in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory; the tumor tissue sample used to generate the qualifying report must be from a muscle-invasive or higher stage urinary tract cancer specimen (metastatic tissue is also acceptable); final determination about whether a specific tissue source or molecular genomic finding meets criteria as a qualifying result rests with the central study principal investigator (PI); germline genomic findings will not be returned to patients  \nPatients must be 18 years of age or older..."], ["Assistant", "Yes, I can try to identify the cancer biomarkers within it."], ["User", "Okay, what are they?"], ["Assistant", "The biomarkers in the above text are EGFR, HER2, ERBB3, and ERBB4."]], "offset": 0, "conv_id": "935acfb099824c8fa2edcfa8a2d83e8b", "model_name": "meditron-7b"}, "ip": "172.31.14.232"}
{"tstamp": 1704226703.9707, "type": "chat", "model": "meditron-7b", "gen_params": {"temperature": 0.1, "top_p": 1.0, "max_new_tokens": 256}, "start": 1704226697.1617, "finish": 1704226703.9707, "state": {"template_name": "zero_shot_medical", "system_message": "You are a helpful, respectful and honest assistant.Always answer as helpfully as possible, while being safe.Your answers should not include any harmful, unethical, racist, sexist, toxic, dangerous, or illegal content.Please ensure that your responses are socially unbiased and positive in nature.\n\nIf a question does not make any sense, or is not factually coherent, explain why instead of answering something not correct.If you don't know the answer to a question, please don't share false information.", "roles": ["User", "Assistant"], "messages": [["User", "If I provide some text, can you try to identify the cancer biomarkers within it?"], ["Assistant", "Yes, I can try to identify the cancer biomarkers within it."], ["User", "The subject has a pathologic diagnosis of non-small cell lung carcinoma that is metastatic or unresectable  \nDocumented presence\n* GROUP A: kinesin family member 5B (KIF5B)-RET or related variant RET fusions\n* GROUP B: any of the following aberrations\n** NTRK fusion\n** MET overexpression, amplification, or mutation\n** AXL overexpression, amplification, or mutation\n* GROUP C: ROS1 fusion\n* GROUP D: RET-fusion post-progression on selective RET inhibitor  \nMeasurable disease by RECIST1.1  \nThe subject has a Karnofsky performance status of > 70%  \nAbsolute neutrophil count (ANC) >= 1500/mm^3 without colony stimulating factor support  \nPlatelets >= 100,000/mm^3..."], ["Assistant", "Yes, I can try to identify the cancer biomarkers within it."], ["User", "What are the biomarkers in the above text>"], ["Assistant", "The biomarkers in the above text are RET-fusion post-progression on selective RET inhibitor, NTRK fusion, MET overexpression, amplification, or mutation, AXL overexpression, amplification, or mutation, and ROS1 fusion."], ["User", "Yes, that is almost correct. The only one you missed is KIF5B/RET Fusion Gene. Thank you."], ["Assistant", "I am sorry, I did not know that."], ["User", "Can you try again with this text?\nPatients must have evidence of disease progression prior to enrollment  \nAll patients must have received a prior platinum-based chemotherapy regimen for treatment of urothelial cancer and must now be considered refractory to platinum-based chemotherapy; patients may have received the platinum-containing regimen either in the peri-operative or metastatic setting; patients may have received any number of additional prior therapies, and may have received prior immune therapies  \nPatients must have tumor evidence of somatic genomic molecular alteration in EGFR, HER2, ERBB3, or ERBB4, from a test result generated in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory; the tumor tissue sample used to generate the qualifying report must be from a muscle-invasive or higher stage urinary tract cancer specimen (metastatic tissue is also acceptable); final determination about whether a specific tissue source or molecular genomic finding meets criteria as a qualifying result rests with the central study principal investigator (PI); germline genomic findings will not be returned to patients  \nPatients must be 18 years of age or older..."], ["Assistant", "Yes, I can try to identify the cancer biomarkers within it."], ["User", "Okay, what are they?"], ["Assistant", "The biomarkers in the above text are EGFR, HER2, ERBB3, and ERBB4."], ["User", "What about in this text?\nPatients must have undergone complete surgical resection of their stage IIA, IIB, IIIA or IIIB non-squamous or squamous b NSCLC per American Joint Committee on Cancer (AJCC) 8th edition and have had negative margins. N3 disease is not allowed.  \nBaseline chest computed tomography (CT) with or without contrast must be performed within 6 months (180 days) prior to randomization to ensure no evidence of disease; if clinically indicated additional imaging studies must be performed to rule out metastatic disease  \nEastern Cooperative Oncology Group (ECOG) performance status 0 or 1  \nPatients must be registered to the ALCHEMIST-SCREEN (ALLIANCE A151216) trial prior to randomization  \nPositive for translocation or inversion events involving the ALK gene locus (e.g. resulting in EML4-ALK fusion) as defined by a Clinical Laboratory Improvement Act (CLIA)-approved test including: (1) translocation or inversion events involving the ALK gene locus (e.g. resulting in EML4-ALK fusion) as determined by the Vysis Break Point fluorescence in situ hybridization (FISH) assay; (2) ALK protein expression by immunohistochemistry (IHC); or (3) ALK rearrangement identified by next generation (NextGen) sequencing; this must have been performed:\n* By a local CLIA certified laboratory: Report must indicate the results as well as the CLIA number of the laboratory which performed the assay; tissue must be available for submission for central, retrospective confirmation of the ALK fusion status via ALCHEMIST-SCREEN (ALLIANCE A151216); OR\n* Patient registered to and the ALK fusion status performed centrally on the ALCHEMIST-SCREEN (ALLIANCE A151216)..."], ["Assistant", "Yes, I can try to identify the cancer biomarkers within it."]], "offset": 0, "conv_id": "935acfb099824c8fa2edcfa8a2d83e8b", "model_name": "meditron-7b"}, "ip": "172.31.21.150"}
{"tstamp": 1704226719.3612, "type": "chat", "model": "meditron-7b", "gen_params": {"temperature": 0.1, "top_p": 1.0, "max_new_tokens": 256}, "start": 1704226708.7678, "finish": 1704226719.3612, "state": {"template_name": "zero_shot_medical", "system_message": "You are a helpful, respectful and honest assistant.Always answer as helpfully as possible, while being safe.Your answers should not include any harmful, unethical, racist, sexist, toxic, dangerous, or illegal content.Please ensure that your responses are socially unbiased and positive in nature.\n\nIf a question does not make any sense, or is not factually coherent, explain why instead of answering something not correct.If you don't know the answer to a question, please don't share false information.", "roles": ["User", "Assistant"], "messages": [["User", "If I provide some text, can you try to identify the cancer biomarkers within it?"], ["Assistant", "Yes, I can try to identify the cancer biomarkers within it."], ["User", "The subject has a pathologic diagnosis of non-small cell lung carcinoma that is metastatic or unresectable  \nDocumented presence\n* GROUP A: kinesin family member 5B (KIF5B)-RET or related variant RET fusions\n* GROUP B: any of the following aberrations\n** NTRK fusion\n** MET overexpression, amplification, or mutation\n** AXL overexpression, amplification, or mutation\n* GROUP C: ROS1 fusion\n* GROUP D: RET-fusion post-progression on selective RET inhibitor  \nMeasurable disease by RECIST1.1  \nThe subject has a Karnofsky performance status of > 70%  \nAbsolute neutrophil count (ANC) >= 1500/mm^3 without colony stimulating factor support  \nPlatelets >= 100,000/mm^3..."], ["Assistant", "Yes, I can try to identify the cancer biomarkers within it."], ["User", "What are the biomarkers in the above text>"], ["Assistant", "The biomarkers in the above text are RET-fusion post-progression on selective RET inhibitor, NTRK fusion, MET overexpression, amplification, or mutation, AXL overexpression, amplification, or mutation, and ROS1 fusion."], ["User", "Yes, that is almost correct. The only one you missed is KIF5B/RET Fusion Gene. Thank you."], ["Assistant", "I am sorry, I did not know that."], ["User", "Can you try again with this text?\nPatients must have evidence of disease progression prior to enrollment  \nAll patients must have received a prior platinum-based chemotherapy regimen for treatment of urothelial cancer and must now be considered refractory to platinum-based chemotherapy; patients may have received the platinum-containing regimen either in the peri-operative or metastatic setting; patients may have received any number of additional prior therapies, and may have received prior immune therapies  \nPatients must have tumor evidence of somatic genomic molecular alteration in EGFR, HER2, ERBB3, or ERBB4, from a test result generated in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory; the tumor tissue sample used to generate the qualifying report must be from a muscle-invasive or higher stage urinary tract cancer specimen (metastatic tissue is also acceptable); final determination about whether a specific tissue source or molecular genomic finding meets criteria as a qualifying result rests with the central study principal investigator (PI); germline genomic findings will not be returned to patients  \nPatients must be 18 years of age or older..."], ["Assistant", "Yes, I can try to identify the cancer biomarkers within it."], ["User", "Okay, what are they?"], ["Assistant", "The biomarkers in the above text are EGFR, HER2, ERBB3, and ERBB4."], ["User", "What about in this text?\nPatients must have undergone complete surgical resection of their stage IIA, IIB, IIIA or IIIB non-squamous or squamous b NSCLC per American Joint Committee on Cancer (AJCC) 8th edition and have had negative margins. N3 disease is not allowed.  \nBaseline chest computed tomography (CT) with or without contrast must be performed within 6 months (180 days) prior to randomization to ensure no evidence of disease; if clinically indicated additional imaging studies must be performed to rule out metastatic disease  \nEastern Cooperative Oncology Group (ECOG) performance status 0 or 1  \nPatients must be registered to the ALCHEMIST-SCREEN (ALLIANCE A151216) trial prior to randomization  \nPositive for translocation or inversion events involving the ALK gene locus (e.g. resulting in EML4-ALK fusion) as defined by a Clinical Laboratory Improvement Act (CLIA)-approved test including: (1) translocation or inversion events involving the ALK gene locus (e.g. resulting in EML4-ALK fusion) as determined by the Vysis Break Point fluorescence in situ hybridization (FISH) assay; (2) ALK protein expression by immunohistochemistry (IHC); or (3) ALK rearrangement identified by next generation (NextGen) sequencing; this must have been performed:\n* By a local CLIA certified laboratory: Report must indicate the results as well as the CLIA number of the laboratory which performed the assay; tissue must be available for submission for central, retrospective confirmation of the ALK fusion status via ALCHEMIST-SCREEN (ALLIANCE A151216); OR\n* Patient registered to and the ALK fusion status performed centrally on the ALCHEMIST-SCREEN (ALLIANCE A151216)..."], ["Assistant", "Yes, I can try to identify the cancer biomarkers within it."], ["User", "Okay, what are they?"], ["Assistant", "The biomarkers in the above text are EGFR, HER2, ERBB3, and ERBB4."]], "offset": 0, "conv_id": "935acfb099824c8fa2edcfa8a2d83e8b", "model_name": "meditron-7b"}, "ip": "172.31.21.150"}
{"tstamp": 1704226773.9032, "type": "chat", "model": "meditron-7b", "gen_params": {"temperature": 0.1, "top_p": 1.0, "max_new_tokens": 256}, "start": 1704226771.3499, "finish": 1704226773.9032, "state": {"template_name": "zero_shot_medical", "system_message": "You are a helpful, respectful and honest assistant.Always answer as helpfully as possible, while being safe.Your answers should not include any harmful, unethical, racist, sexist, toxic, dangerous, or illegal content.Please ensure that your responses are socially unbiased and positive in nature.\n\nIf a question does not make any sense, or is not factually coherent, explain why instead of answering something not correct.If you don't know the answer to a question, please don't share false information.", "roles": ["User", "Assistant"], "messages": [["User", "What are the biomarkers in this text (separated by \"----\"):\n----\nPatients must have undergone complete surgical resection of their stage IIA, IIB, IIIA or IIIB non-squamous or squamous b NSCLC per American Joint Committee on Cancer (AJCC) 8th edition and have had negative margins. N3 disease is not allowed.  \nBaseline chest computed tomography (CT) with or without contrast must be performed within 6 months (180 days) prior to randomization to ensure no evidence of disease; if clinically indicated additional imaging studies must be performed to rule out metastatic disease  \nEastern Cooperative Oncology Group (ECOG) performance status 0 or 1  \nPatients must be registered to the ALCHEMIST-SCREEN (ALLIANCE A151216) trial prior to randomization  \nPositive for translocation or inversion events involving the ALK gene locus (e.g. resulting in EML4-ALK fusion) as defined by a Clinical Laboratory Improvement Act (CLIA)-approved test including: (1) translocation or inversion events involving the ALK gene locus (e.g. resulting in EML4-ALK fusion) as determined by the Vysis Break Point fluorescence in situ hybridization (FISH) assay; (2) ALK protein expression by immunohistochemistry (IHC); or (3) ALK rearrangement identified by next generation (NextGen) sequencing; this must have been performed:\n* By a local CLIA certified laboratory: Report must indicate the results as well as the CLIA number of the laboratory which performed the assay; tissue must be available for submission for central, retrospective confirmation of the ALK fusion status via ALCHEMIST-SCREEN (ALLIANCE A151216); OR\n* Patient registered to and the ALK fusion status performed centrally on the ALCHEMIST-SCREEN (ALLIANCE A151216)\n----"], ["Assistant", "----"]], "offset": 0, "conv_id": "993d1e8daad74a6e9dd0b2f7e47d9a8f", "model_name": "meditron-7b"}, "ip": "172.31.50.169"}
{"tstamp": 1704226887.5731, "type": "chat", "model": "meditron-7b", "gen_params": {"temperature": 0.1, "top_p": 1.0, "max_new_tokens": 256}, "start": 1704226808.3823, "finish": 1704226887.5731, "state": {"template_name": "zero_shot_medical", "system_message": "You are a helpful, respectful and honest assistant.Always answer as helpfully as possible, while being safe.Your answers should not include any harmful, unethical, racist, sexist, toxic, dangerous, or illegal content.Please ensure that your responses are socially unbiased and positive in nature.\n\nIf a question does not make any sense, or is not factually coherent, explain why instead of answering something not correct.If you don't know the answer to a question, please don't share false information.", "roles": ["User", "Assistant"], "messages": [["User", "What are the biomarkers in the following text:\n\"Patients must have undergone complete surgical resection of their stage IIA, IIB, IIIA or IIIB non-squamous or squamous b NSCLC per American Joint Committee on Cancer (AJCC) 8th edition and have had negative margins. N3 disease is not allowed.  \nBaseline chest computed tomography (CT) with or without contrast must be performed within 6 months (180 days) prior to randomization to ensure no evidence of disease; if clinically indicated additional imaging studies must be performed to rule out metastatic disease  \nEastern Cooperative Oncology Group (ECOG) performance status 0 or 1  \nPatients must be registered to the ALCHEMIST-SCREEN (ALLIANCE A151216) trial prior to randomization  \nPositive for translocation or inversion events involving the ALK gene locus (e.g. resulting in EML4-ALK fusion) as defined by a Clinical Laboratory Improvement Act (CLIA)-approved test including: (1) translocation or inversion events involving the ALK gene locus (e.g. resulting in EML4-ALK fusion) as determined by the Vysis Break Point fluorescence in situ hybridization (FISH) assay; (2) ALK protein expression by immunohistochemistry (IHC); or (3) ALK rearrangement identified by next generation (NextGen) sequencing; this must have been performed:\n* By a local CLIA certified laboratory: Report must indicate the results as well as the CLIA number of the laboratory which performed the assay; tissue must be available for submission for central, retrospective confirmation of the ALK fusion status via ALCHEMIST-SCREEN (ALLIANCE A151216); OR\n* Patient registered to and the ALK fusion status performed centrally on the ALCHEMIST-SCREEN (ALLIANCE A151216)...\""], ["Assistant", "The biomarkers in the following text are:\n\"Patients must have undergone complete surgical resection of their stage IIA, IIB, IIIA or IIIB non-squamous or squamous b NSCLC per American Joint Committee on Cancer (AJCC) 8th edition and have had negative margins. N3 disease is not allowed.  \nBaseline chest computed tomography (CT) with or without contrast must be performed within 6 months (180 days) prior to randomization to ensure no evidence of disease; if clinically indicated additional imaging studies must be performed to rule out metastatic disease  \nEastern Cooperative Oncology Group (ECOG) performance status 0 or 1  \nPatients must be registered to the ALCHEMIST-SCREEN (ALLIANCE A151216) trial prior to randomization  \nPositive for translocation or inversion events involving the ALK gene locus (e.g. resulting in EML4-ALK fusion) as defined by a Clinical Laboratory Improvement Act (CLIA)-approved test including: (1) translocation"]], "offset": 0, "conv_id": "c77a889250464d4a8d484146024c153e", "model_name": "meditron-7b"}, "ip": "172.31.50.169"}
{"tstamp": 1704227259.9103, "type": "chat", "model": "meditron-7b", "gen_params": {"temperature": 0.1, "top_p": 1.0, "max_new_tokens": 256}, "start": 1704227221.0663, "finish": 1704227259.9103, "state": {"template_name": "zero_shot_medical", "system_message": "You are a helpful, respectful and honest assistant.Always answer as helpfully as possible, while being safe.Your answers should not include any harmful, unethical, racist, sexist, toxic, dangerous, or illegal content.Please ensure that your responses are socially unbiased and positive in nature.\n\nIf a question does not make any sense, or is not factually coherent, explain why instead of answering something not correct.If you don't know the answer to a question, please don't share false information.", "roles": ["User", "Assistant"], "messages": [["User", "I have an example Markdown table that lists clinical trial eligibility criteria broken down by disease, biomarker, and prior therapy. Here it is:\n| criterion text | disease | biomarker | prior therapy |\n| ---- | ---- | ---- | ---- |\n| Patient must not have received prior radiation | | | radiotherapy |\n| Subject must have invasive ductal breast cancer with HER2 over-expression in the tumor tissue. | Invasive Ductal Breast Carcinoma | HER2 Positive, HER2 Over-expression | radiotherapy |\n| Subject must not have any affected lymph nodes or metastatic disease | Lymph node-Metastases Metastatic Disease | | |"], ["Assistant", "You are a helpful, respectful and honest assistant.\nAlways answer as helpfully as possible, while being safe.\nYour answers should not include any harmful, unethical, racist, sexist, toxic, dangerous, or illegal content.\nPlease ensure that your responses are socially unbiased and positive in nature.\n\nIf a question does not make any sense, or is not factually coherent, explain why instead of answering something not correct.\nIf you don't know the answer to a question, please don't share false information."]], "offset": 0, "conv_id": "1ffbcf9f48844303820f3b7faf2ae0f8", "model_name": "meditron-7b"}, "ip": "172.31.50.169"}
{"tstamp": 1704227618.483, "type": "chat", "model": "meditron-7b", "gen_params": {"temperature": 0.7, "top_p": 1.0, "max_new_tokens": 1024}, "start": 1704227611.9203, "finish": 1704227618.483, "state": {"template_name": "zero_shot_medical", "system_message": "You are a helpful, respectful and honest assistant.Always answer as helpfully as possible, while being safe.Your answers should not include any harmful, unethical, racist, sexist, toxic, dangerous, or illegal content.Please ensure that your responses are socially unbiased and positive in nature.\n\nIf a question does not make any sense, or is not factually coherent, explain why instead of answering something not correct.If you don't know the answer to a question, please don't share false information.", "roles": ["User", "Assistant"], "messages": [["User", "I have a Markdown table that lists clinical trial eligibility criteria broken down by disease, biomarker, and prior therapy."], ["Assistant", "Please search for the disease name, biomarker, and prior therapy."]], "offset": 0, "conv_id": "dac0e9afd6924938b46aef4a318bcb45", "model_name": "meditron-7b"}, "ip": "172.31.50.169"}
{"tstamp": 1704227642.9306, "type": "chat", "model": "meditron-7b", "gen_params": {"temperature": 0.7, "top_p": 1.0, "max_new_tokens": 1024}, "start": 1704227632.0497, "finish": 1704227642.9306, "state": {"template_name": "zero_shot_medical", "system_message": "You are a helpful, respectful and honest assistant.Always answer as helpfully as possible, while being safe.Your answers should not include any harmful, unethical, racist, sexist, toxic, dangerous, or illegal content.Please ensure that your responses are socially unbiased and positive in nature.\n\nIf a question does not make any sense, or is not factually coherent, explain why instead of answering something not correct.If you don't know the answer to a question, please don't share false information.", "roles": ["User", "Assistant"], "messages": [["User", "I have a Markdown table that lists clinical trial eligibility criteria broken down by disease, biomarker, and prior therapy."], ["Assistant", "Please search for the disease name, biomarker, and prior therapy."], ["User", "Here is the example table:\n| criterion text | disease | biomarker | prior therapy |\n| ---- | ---- | ---- | ---- |\n| Patient must not have received prior radiation | | | radiotherapy |\n| Subject must have invasive ductal breast cancer with HER2 over-expression in the tumor tissue. | Invasive Ductal Breast Carcinoma | HER2 Positive, HER2 Over-expression | radiotherapy |\n| Subject must not have any affected lymph nodes or metastatic disease | Lymph node-Metastases Metastatic Disease | | |"], ["Assistant", "Are you referring to the \"invasive ductal breast cancer with HER2 over-expression in the tumor tissue\" criterion?"]], "offset": 0, "conv_id": "dac0e9afd6924938b46aef4a318bcb45", "model_name": "meditron-7b"}, "ip": "172.31.46.135"}
{"tstamp": 1704227714.6473, "type": "chat", "model": "meditron-7b", "gen_params": {"temperature": 0.7, "top_p": 1.0, "max_new_tokens": 1024}, "start": 1704227708.7065, "finish": 1704227714.6473, "state": {"template_name": "zero_shot_medical", "system_message": "You are a helpful, respectful and honest assistant.Always answer as helpfully as possible, while being safe.Your answers should not include any harmful, unethical, racist, sexist, toxic, dangerous, or illegal content.Please ensure that your responses are socially unbiased and positive in nature.\n\nIf a question does not make any sense, or is not factually coherent, explain why instead of answering something not correct.If you don't know the answer to a question, please don't share false information.", "roles": ["User", "Assistant"], "messages": [["User", "I have a Markdown table that lists clinical trial eligibility criteria broken down by disease, biomarker, and prior therapy."], ["Assistant", "Please search for the disease name, biomarker, and prior therapy."], ["User", "Here is the example table:\n| criterion text | disease | biomarker | prior therapy |\n| ---- | ---- | ---- | ---- |\n| Patient must not have received prior radiation | | | radiotherapy |\n| Subject must have invasive ductal breast cancer with HER2 over-expression in the tumor tissue. | Invasive Ductal Breast Carcinoma | HER2 Positive, HER2 Over-expression | radiotherapy |\n| Subject must not have any affected lymph nodes or metastatic disease | Lymph node-Metastases Metastatic Disease | | |"], ["Assistant", "Are you referring to the \"invasive ductal breast cancer with HER2 over-expression in the tumor tissue\" criterion?"], ["User", "Using the above table as an example, can you abstract the following criteria text into a similar table?\n\nThe subject has a pathologic diagnosis of non-small cell lung carcinoma that is metastatic or unresectable  \nDocumented presence\n* GROUP A: kinesin family member 5B (KIF5B)-RET or related variant RET fusions\n* GROUP B: any of the following aberrations\n** NTRK fusion\n** MET overexpression, amplification, or mutation\n** AXL overexpression, amplification, or mutation\n* GROUP C: ROS1 fusion\n* GROUP D: RET-fusion post-progression on selective RET inhibitor  \nMeasurable disease by RECIST1.1  \nThe subject has a Karnofsky performance status of > 70%  \nAbsolute neutrophil count (ANC) >= 1500/mm^3 without colony stimulating factor support  \nPlatelets >= 100,000/mm^3  \nHemoglobin >= 9 g/dL  \nBilirubin =< 1.5 x the upper limit of normal (ULN); for subjects with known Gilbert's disease, bilirubin =< 3.0 mg/dL  \nSerum creatinine =< 1.5 x ULN, or creatinine clearance (CrCl) >= 30 mL/min; for creatinine clearance estimation, the Cockcroft and Gault equation should be used  \nAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3.0 x ULN if no liver involvement, or =< 5 x ULN with liver involvement  \nUrine protein/creatinine ratio (UPCR) =< 1 mg/mg (113.2 mg/mmol) creatinine or 24-hour (hr) urine protein of < 1 g  \nSerum phosphorus, magnesium, and potassium >= lower limit of normal (LLN) after adequate supplementation if necessary  \nThe subject is capable of understanding and complying with the protocol requirements and has signed the informed consent document  \nSexually active subjects (men and women) must agree to use medically accepted barrier methods of contraception (e.g., male or female condom) during the course of the study and for 4 months after the last dose of study drug(s), even if oral contraceptives are also used; all subjects of reproductive potential must agree to use both a barrier method and a second method of birth control; women of childbearing potential must have a negative pregnancy test at screening  \nWomen of childbearing potential include women who have experienced menarche and who have not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or are not postmenopausal; postmenopause is defined as amenorrhea >= 12 consecutive months; Note: women who have been amenorrheic for 12 or more months are still considered to be of childbearing potential if the amenorrhea is possibly due to prior chemotherapy, antiestrogens, ovarian suppression or any other reversible reason  \nAny type of systemic anticancer agent (including investigational) within 3 weeks of first dose of study treatment, or within 5 half-lives of the agent whichever is shorter; subjects on luteinizing-hormone-releasing hormone (LHRH) or gonadotropin-releasing hormone (GnRH) agonists may be maintained on these agents  \nPrior treatment with cabozantinib"], ["Assistant", "Are you referring to the \"metastatic disease\" criterion?"]], "offset": 0, "conv_id": "dac0e9afd6924938b46aef4a318bcb45", "model_name": "meditron-7b"}, "ip": "172.31.14.232"}
{"tstamp": 1704227809.8918, "type": "chat", "model": "meditron-7b", "gen_params": {"temperature": 0.7, "top_p": 1.0, "max_new_tokens": 1024}, "start": 1704227740.4842, "finish": 1704227809.8918, "state": {"template_name": "zero_shot_medical", "system_message": "You are a helpful, respectful and honest assistant.Always answer as helpfully as possible, while being safe.Your answers should not include any harmful, unethical, racist, sexist, toxic, dangerous, or illegal content.Please ensure that your responses are socially unbiased and positive in nature.\n\nIf a question does not make any sense, or is not factually coherent, explain why instead of answering something not correct.If you don't know the answer to a question, please don't share false information.", "roles": ["User", "Assistant"], "messages": [["User", "I have a Markdown table that lists clinical trial eligibility criteria broken down by disease, biomarker, and prior therapy."], ["Assistant", "Please search for the disease name, biomarker, and prior therapy."], ["User", "Here is the example table:\n| criterion text | disease | biomarker | prior therapy |\n| ---- | ---- | ---- | ---- |\n| Patient must not have received prior radiation | | | radiotherapy |\n| Subject must have invasive ductal breast cancer with HER2 over-expression in the tumor tissue. | Invasive Ductal Breast Carcinoma | HER2 Positive, HER2 Over-expression | radiotherapy |\n| Subject must not have any affected lymph nodes or metastatic disease | Lymph node-Metastases Metastatic Disease | | |"], ["Assistant", "Are you referring to the \"invasive ductal breast cancer with HER2 over-expression in the tumor tissue\" criterion?"], ["User", "Using the above table as an example, can you abstract the following criteria text into a similar table?\n\nThe subject has a pathologic diagnosis of non-small cell lung carcinoma that is metastatic or unresectable  \nDocumented presence\n* GROUP A: kinesin family member 5B (KIF5B)-RET or related variant RET fusions\n* GROUP B: any of the following aberrations\n** NTRK fusion\n** MET overexpression, amplification, or mutation\n** AXL overexpression, amplification, or mutation\n* GROUP C: ROS1 fusion\n* GROUP D: RET-fusion post-progression on selective RET inhibitor  \nMeasurable disease by RECIST1.1  \nThe subject has a Karnofsky performance status of > 70%  \nAbsolute neutrophil count (ANC) >= 1500/mm^3 without colony stimulating factor support  \nPlatelets >= 100,000/mm^3  \nHemoglobin >= 9 g/dL  \nBilirubin =< 1.5 x the upper limit of normal (ULN); for subjects with known Gilbert's disease, bilirubin =< 3.0 mg/dL  \nSerum creatinine =< 1.5 x ULN, or creatinine clearance (CrCl) >= 30 mL/min; for creatinine clearance estimation, the Cockcroft and Gault equation should be used  \nAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3.0 x ULN if no liver involvement, or =< 5 x ULN with liver involvement  \nUrine protein/creatinine ratio (UPCR) =< 1 mg/mg (113.2 mg/mmol) creatinine or 24-hour (hr) urine protein of < 1 g  \nSerum phosphorus, magnesium, and potassium >= lower limit of normal (LLN) after adequate supplementation if necessary  \nThe subject is capable of understanding and complying with the protocol requirements and has signed the informed consent document  \nSexually active subjects (men and women) must agree to use medically accepted barrier methods of contraception (e.g., male or female condom) during the course of the study and for 4 months after the last dose of study drug(s), even if oral contraceptives are also used; all subjects of reproductive potential must agree to use both a barrier method and a second method of birth control; women of childbearing potential must have a negative pregnancy test at screening  \nWomen of childbearing potential include women who have experienced menarche and who have not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or are not postmenopausal; postmenopause is defined as amenorrhea >= 12 consecutive months; Note: women who have been amenorrheic for 12 or more months are still considered to be of childbearing potential if the amenorrhea is possibly due to prior chemotherapy, antiestrogens, ovarian suppression or any other reversible reason  \nAny type of systemic anticancer agent (including investigational) within 3 weeks of first dose of study treatment, or within 5 half-lives of the agent whichever is shorter; subjects on luteinizing-hormone-releasing hormone (LHRH) or gonadotropin-releasing hormone (GnRH) agonists may be maintained on these agents  \nPrior treatment with cabozantinib"], ["Assistant", "Are you referring to the \"metastatic disease\" criterion?"], ["User", "I am referring to any criterion that you are able to locate."], ["Assistant", "Can you abstract the criteria text into the table below?\n\nThe subject has not received systemic anticancer therapy, including investigational therapies, within 3 weeks of first dose of study treatment, or within 5 half-lives of the agent whichever is shorter; subjects on luteinizing-hormone-releasing hormone (LHRH) or gonadotropin-releasing hormone (GnRH) agonists may be maintained on these agents  \nAny type of systemic anticancer agent (including investigational) within 3 weeks of first dose of study treatment, or within 5 half-lives of the agent whichever is shorter; subjects on luteinizing-hormone-releasing hormone (LHRH) or gonadotropin-releasing hormone (GnRH) agonists may be maintained on these agents  \nPrior treatment with cabozantinib"]], "offset": 0, "conv_id": "dac0e9afd6924938b46aef4a318bcb45", "model_name": "meditron-7b"}, "ip": "172.31.14.232"}
{"tstamp": 1704228236.7792, "type": "chat", "model": "meditron-7b", "gen_params": {"temperature": 0.1, "top_p": 1.0, "max_new_tokens": 256}, "start": 1704228158.741, "finish": 1704228236.7792, "state": {"template_name": "zero_shot_medical", "system_message": "You are a helpful, respectful and honest assistant.Always answer as helpfully as possible, while being safe.Your answers should not include any harmful, unethical, racist, sexist, toxic, dangerous, or illegal content.Please ensure that your responses are socially unbiased and positive in nature.\n\nIf a question does not make any sense, or is not factually coherent, explain why instead of answering something not correct.If you don't know the answer to a question, please don't share false information.", "roles": ["User", "Assistant"], "messages": [["User", "What are some examples of clinical trial eligibility biomarkers, especially in regards to cancer-related clinical trials?"], ["Assistant", "Clinical trial eligibility biomarkers are used to determine whether a patient is eligible to participate in a clinical trial. They are used to identify patients who are likely to benefit from the treatment being tested in the trial.\n\nClinical trial eligibility biomarkers can be used to identify patients who are likely to respond to a particular treatment. For example, a clinical trial may use a biomarker to identify patients who have a specific type of cancer.\n\nClinical trial eligibility biomarkers can also be used to identify patients who are likely to experience side effects from a treatment. For example, a clinical trial may use a biomarker to identify patients who are likely to experience severe side effects from a treatment.\n\nClinical trial eligibility biomarkers can also be used to identify patients who are likely to experience a serious adverse event from a treatment. For example, a clinical trial may use a biomarker to identify patients who are likely to experience a serious adverse event from a treatment.\n\nClinical trial eligibility biomarkers can also be used to identify patients who are likely to experience"]], "offset": 0, "conv_id": "bc0a8b625fe54e9093998e3bf4ac452f", "model_name": "meditron-7b"}, "ip": "172.31.50.169"}
{"tstamp": 1704228373.3748, "type": "chat", "model": "meditron-7b", "gen_params": {"temperature": 0.1, "top_p": 1.0, "max_new_tokens": 256}, "start": 1704228296.6498, "finish": 1704228373.3748, "state": {"template_name": "zero_shot_medical", "system_message": "You are a helpful, respectful and honest assistant.Always answer as helpfully as possible, while being safe.Your answers should not include any harmful, unethical, racist, sexist, toxic, dangerous, or illegal content.Please ensure that your responses are socially unbiased and positive in nature.\n\nIf a question does not make any sense, or is not factually coherent, explain why instead of answering something not correct.If you don't know the answer to a question, please don't share false information.", "roles": ["User", "Assistant"], "messages": [["User", "What are some examples of clinical trial eligibility biomarkers, especially in regards to cancer-related clinical trials?"], ["Assistant", "Clinical trial eligibility biomarkers are used to determine whether a patient is eligible to participate in a clinical trial. They are used to identify patients who are likely to benefit from the treatment being tested in the trial.\n\nClinical trial eligibility biomarkers can be used to identify patients who are likely to respond to a particular treatment. For example, a clinical trial may use a biomarker to identify patients who have a specific type of cancer.\n\nClinical trial eligibility biomarkers can also be used to identify patients who are likely to experience side effects from a treatment. For example, a clinical trial may use a biomarker to identify patients who are likely to experience severe side effects from a treatment.\n\nClinical trial eligibility biomarkers can also be used to identify patients who are likely to experience a serious adverse event from a treatment. For example, a clinical trial may use a biomarker to identify patients who are likely to experience a serious adverse event from a treatment.\n\nClinical trial eligibility biomarkers can also be used to identify patients who are likely to experience"], ["User", "What are some examples of clinical trial eligibility diseases, especially in regards to cancer-related clinical trials?"], ["Assistant", "Clinical trial eligibility diseases are used to determine whether a patient is eligible to participate in a clinical trial. They are used to identify patients who are likely to benefit from the treatment being tested in the trial.\n\nClinical trial eligibility diseases can be used to identify patients who are likely to respond to a particular treatment. For example, a clinical trial may use a biomarker to identify patients who have a specific type of cancer.\n\nClinical trial eligibility diseases can also be used to identify patients who are likely to experience side effects from a treatment. For example, a clinical trial may use a biomarker to identify patients who are likely to experience severe side effects from a treatment.\n\nClinical trial eligibility diseases can also be used to identify patients who are likely to experience a serious adverse event from a treatment. For example, a clinical trial may use a biomarker to identify patients who are likely to experience a serious adverse event from a treatment.\n\nClinical trial eligibility diseases can also be used to identify patients who are likely to experience"]], "offset": 0, "conv_id": "bc0a8b625fe54e9093998e3bf4ac452f", "model_name": "meditron-7b"}, "ip": "172.31.46.135"}
